Video Interview: Dr. Dale Schenk, Chief Executive Officer, Prothena Corporation plc [PRTA]

NASDAQ CEO Signature Series Logo

NEW YORK, Feb. 19, 2013 (GLOBE NEWSWIRE) -- Veteran business journalist Carmen Roberts joins Dr. Dale Schenk, Chief Executive Officer, Prothena Corporation plc [PRTA] to discuss the company's industry, strategy, financials and positioning.

Click here to view video:

Dr. Dale Schenk, Chief Executive Officer of Prothena, was most recently Chief Scientific Officer and Executive Vice President at Elan Pharmaceuticals where he provided the leadership and scientific direction for Elan's research and development programs. Prior to joining Elan, Dr. Schenk was a founding scientist of Athena Neurosciences which was acquired by Elan Pharmaceuticals. Dr. Schenk has pioneered the immunotherapeutic approach for the treatment of amyloidosis, as exemplified for Alzheimer's disease. Dr. Schenk's work in this area – as well as in early detection, testing and other pathways to the disease – has led to the most advanced potential treatment approaches for Alzheimer's disease. Dr. Schenk earned his BA and PhD in Pharmacology and Physiology from the University of California, San Diego.


Prothena Corporation plc (Nasdaq:PRTA) is a biotechnology company focused on the discovery and development of novel antibodies for the potential treatment of a broad range of diseases that involve protein misfolding or cell adhesion, particularly on the discovery and development of potential therapeutic monoclonal antibodies directed specifically to disease-causing proteins. These potential therapies have a broad range of indications, including AL and AA forms of amyloidosis, Parkinson's disease and related synucleinopathies, and novel cell adhesion targets involved in autoimmune disease and metastatic cancers. For more information, please visit

For more information on the opportunity to have your CEO discuss your company, please call NASDAQ CEO Signature Series, 978/461-3141.

The NASDAQ CEO Signature Series logo is available at

Source: NASDAQ CEO Signature Series;Prothena Corporation plc